HNSCC, primarily developing in the mucosal linings of the mouth and throat, remains a formidable health challenge worldwide due to its aggressive nature and poor prognosis when detected late. Despite advances in oncology, recent pharmaceutical developments have struggled to meaningfully enhance five-year survival rates or improve the quality of life for patients suffering from this malignancy. Daniell underscores the urgent necessity for therapies that specifically target microbial contributors to cancer progression, paving the way for a more tailored, multifaceted treatment landscape.

Building on prior work involving a plant-based chewing gum derived from lablab beans and enriched with FRIL, a naturally occurring antiviral protein, Daniell’s study delves into the gum’s effects on key oncogenic microbes within oral environments. The three focal microorganisms—human papilloma virus (HPV), along with two bacterial species, Porphyromonas gingivalis and Fusobacterium nucleatum—are increasingly recognized not merely as coincidental inhabitants but as active facilitators in the carcinogenesis and progression of HNSCC.

HPV infection has gained particular attention due to its rapidly increasing role in oropharyngeal cancers worldwide. Epidemiological data underscore a direct correlation between HPV presence and a surge in oropharyngeal carcinoma cases. Meanwhile, P. gingivalis and F. nucleatum, anaerobic bacteria frequently present in periodontal diseases, have been implicated in exacerbating oral cancer outcomes. The persistent colonization of these bacteria is linked to inflammation-mediated tumorigenesis, diminished treatment response, and reduced survival rates, especially in the recurrent and metastatic settings.

Daniell’s team utilized clinical saliva and oral rinse samples from HNSCC patients to evaluate microbial load before and after treatment with the bioengineered gums. Remarkably, the lablab bean gum extracts containing FRIL achieved a 93% reduction in HPV levels in saliva and an 80% decrease in oral rinse samples. These antiviral properties mark a significant stride in non-invasive, patient-friendly cancer adjunct therapies aimed at directly diminishing viral oncogenic drivers.

To further enhance the therapeutic profile, the researchers introduced protegrin—an antimicrobial peptide with potent bactericidal activity—into the gum framework. Protegrin’s inclusion proved transformative, driving P. gingivalis and F. nucleatum levels down to virtually undetectable amounts following a single dose application. This selective antimicrobial effect is critically distinct from conventional cancer therapies such as radiation, which indiscriminately destroy beneficial oral microbiota and inadvertently foster opportunistic infections, notably with Candida albicans.

The significance of these findings resonates profoundly within the context of global cancer epidemiology. Lip and oral cavity cancers were ranked as the seventh leading type in incidence and mortality rates among adolescents, young adults, and middle-aged populations worldwide in 2022. Current treatment modalities often fail to address the microbial dimension of HNSCC pathogenesis, underscoring Daniell’s gum formulation as a potentially transformative prophylactic and adjuvant treatment modality.

Importantly, the gum’s specificity in targeting pathogenic microbes while sparing commensal oral flora addresses a critical shortcoming of prevailing antimicrobial approaches. Preservation of the beneficial microbiome is fundamental for maintaining oral homeostasis, immunity, and overall health. The ability to reduce carcinogenic microbes without collateral damage represents a paradigm shift in cancer supportive care.

The study’s ex vivo design—which analyzed clinical samples outside the living body—provides strong proof-of-concept evidence, but further clinical trials are imperative to translate these promising results into viable, widely accessible therapies. Daniell advocates for the advancement of this technology into human trials as adjuvant therapies alongside existing treatment regimens or as preventive measures aimed at reducing infection and transmission risks in at-risk populations.

These findings open exciting avenues for bioengineering and pharmaceutical innovation, demonstrating how natural plant-based platforms can be harnessed to develop next-generation biologics with dual antiviral and antibacterial properties. Beyond cancer, such strategies might well extend to combat microbial drivers of other chronic diseases, given the centrality of the microbiome in human health and disease.

Henry Daniell, holding the W.D. Miller Professorship in the Department of Basic & Translational Sciences, emphasizes that the gum-based delivery system’s ease of use, affordability, and targeted efficacy could profoundly democratize access to cancer adjunct therapies, especially in low-resource settings where advanced pharmaceutical interventions remain scarce.

The multidisciplinary collaboration among Penn Dental Medicine, the University of Kansas Medical Center, UCLA, and the Veterans Administration Greater Los Angeles Healthcare System highlights the compelling synergy between innovative materials science, microbiology, and clinical oncology necessary to pioneer such novel therapeutic modalities.

Funding support from the NIH, David Geffen School of Medicine at UCLA, and the National Cancer Institute Cancer Center reflects a robust commitment from leading health agencies to back groundbreaking explorations that challenge traditional paradigms and aspire to elevate patient outcomes in head and neck cancers.

As this research progresses, the prospect of mitigating cancer progression through a simple, bioengineered chewing gum merges cutting-edge scientific innovation with practical patient care, symbolizing a hopeful advance toward more effective, less toxic cancer prevention and management strategies.

Subject of Research: Human tissue samples
Article Title: Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes
News Publication Date: 9-Feb-2026
Web References: 10.1038/s41598-026-39062-w
Keywords: Head and neck cancer, Oral cancer, Antiviral activity, Antibiotic activity, Antivirals, Saliva

Salivary gland cancers, although rare, pose significant therapeutic challenges owing to their heterogeneity and the anatomical intricacies of the head and neck region. Traditional treatments, including surgery, radiation, and chemotherapy, frequently fail to deliver durable responses, particularly for advanced-stage disease. The discovery that a subset of these tumors retains a wild-type TP53 gene—a critical tumor suppressor known as the “guardian of the genome”—has opened up novel avenues for therapeutic intervention. It is within this molecular context that Alrizomadlin emerges as a compelling candidate, given its function as a potent antagonist of the MDM2 protein.

At the molecular level, MDM2 serves as a principal negative regulator of TP53, binding to and marking it for degradation. In many cancers, overexpressed MDM2 diminishes the tumor-suppressive activities of TP53, undermining apoptosis, cell cycle arrest, and DNA repair pathways. By inhibiting MDM2, Alrizomadlin effectively frees TP53 from its constraints, reinstating its ability to mediate cellular responses to oncogenic stress. The compound’s design leverages a nuanced understanding of the TP53-MDM2 interaction interface, enabling a precision strike that selectively targets tumors harboring wild-type TP53, thereby sparing normal tissues that rely on intact TP53 signaling.

The phase I clinical trial aimed primarily to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Alrizomadlin in patients with advanced salivary gland cancers possessing wild-type TP53. Employing a dose-escalation framework, the study enrolled a cohort of patients resistant to conventional therapies or ineligible for standard treatment modalities. The trial’s design reflected a meticulous integration of translational research, incorporating serial tumor biopsies, circulating tumor DNA assessments, and functional imaging to elucidate mechanistic insights and biological responses elicited by the drug.

Preliminary findings from the trial were highly encouraging. Patients receiving Alrizomadlin exhibited manageable adverse effects, predominantly grade 1 and 2 hematological and gastrointestinal toxicities, which were reversible and consistent with the mode of action of MDM2 inhibition. Importantly, dose-limiting toxicities were infrequent, allowing the identification of a recommended phase II dose that balanced efficacy and patient safety. Pharmacokinetic analyses demonstrated favorable oral bioavailability and dose-proportional systemic exposure, suggesting robust therapeutic potential.

From an efficacy perspective, a proportion of patients showed marked tumor regression or prolonged disease stabilization. Radiological responses correlated with molecular markers of TP53 pathway reactivation, including upregulated expression of downstream targets such as p21 and MDM2 itself, confirming the on-target activity of Alrizomadlin. These data reaffirm the paradigm that re-engagement of endogenous tumor suppressor networks can elicit substantial antitumor effects, even in cancers previously considered refractory to conventional interventions.

Mechanistically, the reinstitution of TP53 function by MDM2 antagonism induces a multifaceted cellular response. Beyond triggering apoptosis, this pathway can activate senescence and disrupt tumor microenvironment interactions, thereby hampering cancer proliferation and invasiveness. Notably, the interplay between TP53 restoration and immune modulation remains an area of active investigation, with emerging evidence suggesting that TP53 activation can enhance immune system recognition of tumor cells, potentially synergizing with immunotherapeutic strategies.

The trial also highlighted the importance of rigorous patient selection based on molecular diagnostics. The precise determination of TP53 status was critical for enrolling patients most likely to derive benefit from Alrizomadlin, emphasizing the role of next-generation sequencing and other genomic tools in guiding personalized therapy. This tailored approach underscores the broader shift in oncology toward biomarker-driven drug development, optimizing therapeutic indices and circumventing unnecessary toxicity.

Furthermore, researchers noted the drug’s capacity to overcome intrinsic and acquired resistance mechanisms commonly encountered in salivary gland cancers. By targeting the fundamental regulatory node of the TP53-MDM2 axis, Alrizomadlin disrupts a central oncogenic conduit, which may also curtail compensatory survival pathways exploited by tumor cells. The broad biological implications of this inhibition were exemplified by the attenuation of metastatic potential and tumor stemness observed in several preclinical models included as part of the translational arm of the study.

The success of this phase I trial catalyzes several exciting future directions for the clinical development of Alrizomadlin. Planned phase II studies aim to validate its efficacy in larger cohorts, explore combinatorial regimens with immune checkpoint inhibitors, and assess its utility across other TP53 wild-type malignancies. Additionally, ongoing research is delving into optimizing dosing schedules and investigating biomarkers predictive of response and resistance to fine-tune patient care further.

From a therapeutic landscape perspective, Alrizomadlin represents a triumph of targeted oncology drug discovery, illuminating a novel therapeutic axis that capitalizes on restoring endogenous tumor suppressor functions. This approach contrasts with the more common strategy of inhibiting oncogenes or signaling pathways directly, instead revitalizing the cell’s innate genomic surveillance machinery, which may confer superior durability and depth of response.

In sum, the investigation of MDM2 inhibition with Alrizomadlin in TP53 wild-type salivary gland cancers heralds a promising paradigm shift in precision medicine. The drug’s capacity to safely and effectively reactivate TP53, induce tumor regression, and modulate the tumor microenvironment sets a new benchmark for targeted therapies in a traditionally intractable cancer domain. As further clinical data emerges, Alrizomadlin is poised to redefine treatment standards and drive innovation in the quest to harness the full power of tumor suppressor restoration.

This seminal study not only broadens the therapeutic horizon for patients afflicted with salivary gland cancers but also provides a valuable blueprint for exploiting MDM2 inhibition in diverse oncological settings. The researchers’ commitment to integrating robust molecular characterizations with clinical insights exemplifies the future of oncology—a future in which exquisitely tailored therapies eradicate cancer by restoring the fundamental cellular processes designed to prevent it. As the scientific and medical community awaits subsequent trial phases with anticipation, Alrizomadlin stands as a beacon of hope and a testament to the transformative potential of targeted cancer therapies.

Subject of Research:
MDM2 inhibition with Alrizomadlin (APG-115) as a therapeutic strategy for TP53 wild-type salivary gland cancers.

Article Title:
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.

Article References:
Pearson, A.T., Muzaffar, J., Kirtane, K. et al. MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70653-3

Image Credits: AI Generated